Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

CABERGOLINE 0.5 MG TABLET

CABERGOLINE
$1.4361per EA

Strength

.5 mg/1

Manufacturer

Somerset Therapeutics, LLC

NDC

70069082408

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

CABERGOLINE

Approval Type

Generic (ANDA)

FDA Application

ANDA218109

On Market Since

10/18/2024

Pharmacological Classes

Ergolines
Ergot Derivative

Price History

1W

0.0%

1M

+1.5%

3M

+5.9%

6M

-4.0%

1Y

-11.2%

3Y

N/A

5Y

N/A

All

-2.9%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

CABERGOLINE 0.5 MG TABLET
Generic
00093542088•Teva Pharmaceuticals USA Inc.
$1.4361
per EA
CABERGOLINE 0.5 MG TABLET
Generic
23155082373•Heritage Pharmaceuticals Inc.
$1.4361
per EA
CABERGOLINE 0.5 MG TABLET
Generic
50742011808•Ingenus Pharmaceuticals LLC
$1.4361
per EA
CABERGOLINE 0.5 MG TABLET
Generic
59762100501•Mylan Pharmaceuticals Inc.
$1.4361
per EA
CABERGOLINE 0.5 MG TABLET
Generic
69238269301•Amneal Pharmaceuticals NY LLC
$1.4361
per EA
CABERGOLINE 0.5 MG TABLET
Generic
70512086008•SOLA Pharmaceuticals LLC
$1.4361
per EA
BROMOCRIPTINE 2.5 MG TABLET
Generic
00781532501•Sandoz Inc.
$1.5691
per EA
BROMOCRIPTINE 2.5 MG TABLET
Generic
00781532531•Sandoz Inc.
$1.6800
per EA
BROMOCRIPTINE 2.5 MG TABLET
Generic
00574010601•Padagis US LLC
$1.6927
per EA
BROMOCRIPTINE 2.5 MG TABLET
Generic
00574010603•Padagis US LLC
$1.6927
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy